Biochemical Heterogeneity in Schizophrenia: Implications and Research Strategies of the State Dependency Model

  • D. P. Van Kammen
Conference paper


Clinical heterogeneity in schizophrenia has limited interest unless we can validate it in terms of etiology, prognosis, or treatment response (Garver et al. 1988; Brown et al. 1990). Similarly, biochemical heterogeneity is not very interesting if it does not lead to etiological heterogeneity or clinical application. Traditional research strategies have been confounded by the fact that the study of schizophrenic patients is very difficult. The very nature of the disorder interferes with the patients’ willingness and ability to participate in research (and in clinical care). Therefore, most studies make use of cross-sectional study designs, based on the notion that the study variable is stable over time. The difficulties in replicating such findings are usually explained by invoking the heterogeneity in etiology hypothesis, which explains much but clarifies nothing.


Schizophrenic Patient Drug Response BioI Psychiatry Schizotypal Personality Disorder Premorbid Functioning 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Akbarian S, Viñuela A, Kim JJ, Potkin SG, Bunney WE Jr, Jones EG (1993) Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 50:178–187PubMedGoogle Scholar
  2. Albus M, Ackenheil M, Engel RR, Muller F (1982) Situational reactivity of autonomic functions in schizophrenic patients. Psychiatry Res 6:361–370PubMedCrossRefGoogle Scholar
  3. Andrews P, Hall JN, Snaith RP (1976) A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients. Br J Psychiatry 128:451–455PubMedCrossRefGoogle Scholar
  4. Angrist B, van Kammen (1984) CNS stimulants as tools in the study of schizophrenia. Trends Neurosci 7:388–390CrossRefGoogle Scholar
  5. Angrist B, Peselow E, Rotrosen J, Gershon S (1981) Relationships between responses to dopamine agonists, psychopathology, neuroleptic treatment response, and need for neuroleptic maintenance in schizophrenic subjects. In: Angrist B, Burrows BD, Lader M, Lingjaerde O, Sedvall G, Wheatley D (eds) Recent advances in neuropsychopharmacology. Permagon, New York, pp 49–54Google Scholar
  6. Angrist B, Peselow E, Rubinstein M, Wolkin A, Rotrosen J (1985) Amphetamine response and relapse risk after depot neuroleptic discontinuation. Psychopharmacology 85:277–283PubMedCrossRefGoogle Scholar
  7. Benes FM (1991) Evidence for neurodevelopment disturbances in anterior cingulated cortex of post-mortem schizophrenic brain. Schizophr Res 5:187–188PubMedCrossRefGoogle Scholar
  8. Bilder RM, Mukherjee S, Rieder RO, Pandurangi AK (1985) Symptomatic and neuropsychological components of defect states. Schizophr Bull 11:409–419PubMedGoogle Scholar
  9. Bondy B, Ackenheil M, Birzle W, Elbers R, Frohler M (1984) Catecholamines and their receptors in blood: evidence for alterations in schizophrenia. Biol Psychiatry 19:1377–1393PubMedGoogle Scholar
  10. Bowers MB Jr, Swigar ME, Jatlow PI, Hoffman F, Giocoechea N (1986) Early neuroleptic response in psychotic men and women: correlation with plasma HVA and MHPG. Compr Psychiatry 27:181–185PubMedCrossRefGoogle Scholar
  11. Breier A (1989) Experimental approaches to human stress research: assessment of neurobiological mechanisms of stress in volunteers and psychiatric patients. Biol Psychiatry 26:438–462PubMedCrossRefGoogle Scholar
  12. Brown WA, Laughren TP (1981) Low serum prolactin and early relapse during neuroleptic treatment and withdrawal. Am J Psychiatry 136:237–239Google Scholar
  13. Brown WA, Herz LR (1987) Response to neuroleptic drugs as a device for classifying schizophrenia. Schizophr Bull 15:123–129Google Scholar
  14. Brown GM, Mazurek M, Allen D, Szechtman B, Cleghorn JM (1990) Dose-response profiles of plasma growth hormone and vasopressin after Clonidine challenge in man. Psychiatry Res 31:311–320PubMedCrossRefGoogle Scholar
  15. Buchanan RW, Kirkpatrick B, Summerfelt A, Hanlon TE, Levine J, Carpenter WT Jr (1992) Clinical predictors of relapse following neuroleptic withdrawal. Biol Psychiatry 32:72–78PubMedCrossRefGoogle Scholar
  16. Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140–144CrossRefGoogle Scholar
  17. Carpenter WT (1989) Dissecting schizophrenia through psychopathology, monograph. The 1989 Charles Burlingame Award Lecture. Institute of Living, Hartford, CTGoogle Scholar
  18. Carpenter WT Jr, Heinrichs DW, Wagman AMI (1988) Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 145:578–583PubMedGoogle Scholar
  19. Chang W-H, Chen T-Y, Lin S-K, Lung F-W, Lin W-L, Hu W-H, Yeh E-K (1990) Plasma catecholamine metabolites in schizophrenics: Evidence for the two-subtype concept. Biol Psychiatry 27:510–518PubMedCrossRefGoogle Scholar
  20. Cleghorn JM, Brown GM, Brown PJ, Kaplan RD, Dermer SW, MacCrimmon DJ, Mitton J (1983) Growth hormone responses to apomorphine HCl in schizophrenic patients on drug holidays and at relapse. Br J Psychiatry 142:482–488PubMedCrossRefGoogle Scholar
  21. Condray R, Steinhauer SR (1992) Schizotypal personality disorder in individuals with and without schizophrenic relatives: similarities and contrasts in neurocognitive and clinical functioning. Schizophr Res 7:33–41PubMedCrossRefGoogle Scholar
  22. Coyle JT, Snyder SH (1969) Catecholamine uptake by synaptosomes in homogenates of rat brain. Stereospecificity in different areas. J Pharmacol Exp Ther 170:221–231PubMedGoogle Scholar
  23. Crawley JCW, Owens DGC, Crow TJ, Poulter M, Johnstone EC, Smith T, Oldland SRD, Veall N, Owen F, Zanelli GD (1986) Dopamine D2 receptors in schizophrenia studied in vivo. Lancet 2:224–225PubMedCrossRefGoogle Scholar
  24. Crow TJ, Owen F, Cross AJ, Johnstone EC, Joseph MH, Longden A (1980) The dopamine receptor as the site of the primary disturbance in the type-I syndrome of schizophrenia. In: Usdin E, Sourkes Tl, Youdim MBH (eds) Enzymes and neurotransmitters in mental disease. Wiley, New York, pp 559–572Google Scholar
  25. Davidson M, Davis KL (1988) A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. Arch Gen Psychiatry 45:561–563PubMedGoogle Scholar
  26. Davidson M, Keefe RSE, Mohs RC, Siever LJ, Losonczy MF, Horvath TB, Davis KL (1987) L-dopa challenge and relapse in schizophrenia. Am J Psychiatry 144:934–938PubMedGoogle Scholar
  27. Davila R, Manero E, Zumarraga M, Andia I, Schweitzer JW, Friedhoff AJ (1988) Plasma homovanillic acid as a predictor of response to neuroleptics. Arch Gen Psychiatry 45:561–563Google Scholar
  28. Davis KL, Davidson M, Mohs RC, Kendler KS, Davis BM, Johns CA, DeNigris Y, Horvath TB (1985) Plasma homovanillic acid concentration and the severity of schizophrenic illness. Science 227:1601–1602PubMedCrossRefGoogle Scholar
  29. Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148:1474–1486PubMedGoogle Scholar
  30. Dencker SJ, Malm U, Lepp M (1986) Schizophrenic relapse after drug withdrawal is predictable. Acta Psychiatr Scand 73:181–185PubMedCrossRefGoogle Scholar
  31. Delisi LE, Dauphinais D (1989) Neuroleptic responsiveness in siblings concordant for schizophrenia. Arch Gen Psychiatry 46:477PubMedGoogle Scholar
  32. Docherty JP, van Kammen DP, Siris SG, Marder SR (1978) Stages of onset of schizophrenic psychosis. Am J Psychiatry 135:420–426PubMedGoogle Scholar
  33. Farde L, Wiesel F, Stone-Elander S, Halldin C, Nordstrom A, Hall H, Sedvall G (1990) D2 dopamine receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatry 47:213–219PubMedGoogle Scholar
  34. Friedhoff A J (1986) A dopamine-dependent resitutive system for the maintenance of mental normalcy. Ann NY Acad Sci 463:47–52PubMedCrossRefGoogle Scholar
  35. Garver DL, Kelly K, Fried KA, Magnusson M, Hirschowitz J (1988) Drug response patterns as a basis of nosology for the mood-incongruent psychoses (the schizophrenias). Psychol Med 18:1–13CrossRefGoogle Scholar
  36. Gattaz WF, Riederer P, Reynolds GP, Gattaz D, Beckmann H (1983) Dopamine and noradrenaline in the cerebrospinal fluid of schizophrenic patients. Psychiatry Res 8:243–250PubMedCrossRefGoogle Scholar
  37. Gillin JC, Kaplan J, Stillman R, Wyatt RJ (1976) The psychedelic model of schizophrenia: the case of N, N-dimethyltryptamine. Am J Psychiatry 133:203–214PubMedGoogle Scholar
  38. Green AI, Faraone SV, Brown WA (1990) Prolactin shifts after neuroleptic withdrawal. Psychiatry Res 32:213–219PubMedCrossRefGoogle Scholar
  39. Heinrichs DW, Carpenter WT Jr (1985) Prospective study of prodromal symptoms in schizophrenic relapse. Am J Psychiatry 142:371–373PubMedGoogle Scholar
  40. Henn FA, Henn SW (1982) Phospholipids as markers for schizophrenia. In: Usdin E, Hanin I (eds) Biological markers in psychiatry and neurology. Permagon New York, pp 183–185Google Scholar
  41. Herz MI, Szymanski HV, Simon JC (1982) Intermittent medication for stable schizophrenic outpatients: an alternative to maintenance medication. Am J Psychiatry 139:917–922Google Scholar
  42. Herz MI, Glazer WM, Mostert A, Sheard MA, Szymanski HV, Hafez H, Mirza M, Vana J (1991) Intermittent vs. maintenance medication in schizophrenia. Arch Gen Psychiatry 48:333–339PubMedGoogle Scholar
  43. Hirsch SR, Jolley AG, Morrison E, McRink A, Wilson L (1990) Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at 2 years. Schizophr Res 3:40CrossRefGoogle Scholar
  44. Holzman PS, Kringlen E, Matthysse S, Flanagan SD, Lipton RB, Cramer G, Levin S, Lange K, Levy DL (1988) A single dominant gene can account for eye tracking dysfunctions and schizophrenia in offspring of discordant twins. Arch Gen Psychiatry 45:641–647PubMedGoogle Scholar
  45. Hornykiewicz O (1982) Brain catecholamine in schizophrenia — a good case for noradrenaline. Nature 299:484–486PubMedCrossRefGoogle Scholar
  46. Innis RB, Malison RT, Al-Tikriti M, Hoffer PB, Sybirska EH, Seibyl JP, Zoghbi SS, Baldwin RM, Laruelle M, Smith EO, Charney DS, Heninger G, Eisworth JD, Roth RH (1992) Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates. Synapse 10:177–184PubMedCrossRefGoogle Scholar
  47. Jakob H, Beckmann H (1986) Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J Neural Transm 65:303–326PubMedCrossRefGoogle Scholar
  48. Janowsky DS, Davis JM (1976) Methylphenidate, dextroamphetamine, and levam-phetamine: effects on schizophrenic symptoms. Arch Gen Psychiatry 33:304–308PubMedGoogle Scholar
  49. Janowsky DS, El-Yousef K, Davis JM, Sekerke HJ (1973) Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch Gen Psychiatry 28:185–191PubMedGoogle Scholar
  50. Johnson DAW (1976) The expectation of outcome from maintenance therapy in chronic schizophrenic patients. Br J Psychiatry 128:246–250PubMedCrossRefGoogle Scholar
  51. Johnson DAW, Pasterski G, Ludlow JM, Street K, Taylor RDW (1983) The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand 67:339–352PubMedCrossRefGoogle Scholar
  52. Johnstone EC, Owens DGC, Frith CD, Crow TJ (1986) The relative stability of positive and negative features in chronic schizophrenia. Br J Psychiatry 150:60–64CrossRefGoogle Scholar
  53. Kafka MS, van Kammen DP, Kleinman JE (1980) α-Adrenergic receptor function in schizophrenia. Psychopharmacol Bull 16:91–94Google Scholar
  54. Kafka MS, van Kammen DP (1983) α-Adrenergic receptor function in schizophrenia. Arch Gen Psychiatry 40:264–270PubMedGoogle Scholar
  55. Kafka MS, Siever LJ, Nürnberger JI, Uhde TW, Targum S. Cooper DMJ, van Kammen DP, Tokola NS (1985) Platelet alpha-adrenergic receptor function in affective disorders and schizophrenia. Psychopharmacol Bull 21:599–602PubMedGoogle Scholar
  56. Kane J, Honigfeld G, Singer J, Meitzer H (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789–796PubMedGoogle Scholar
  57. Kanof PD, Johns CA, Davidson M, Siever LJ, Coccaro EF, Davis KL (1988) Platelet alpha2-adrenergic receptor function in psychiatric disorders. Psychiatry Res 23: 11–22PubMedCrossRefGoogle Scholar
  58. Karoum F, Karson CN, Bigelow LB, Lawson WB, Wyatt RJ (1987) Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia. Arch Gen Psychiatry 44:604–607PubMedGoogle Scholar
  59. Kay SR, Sevy S (1990) Pyramidical model of schizophrenia. Schizophr Bull 16:537–545PubMedGoogle Scholar
  60. Keefe RSE, Mohs RC, Losonczy MF, Davidson M, Silverman JM, Kendler KS, Horvath TB, Nora R, Davis KL (1987) Characteristics of very poor outcome schizophrenia. Am J Psychiatry 144:889–895PubMedGoogle Scholar
  61. Kelley ME, Gilbertson M, Mouton A, van Kammen DP (1992) Deterioration in premorbid functioning in schizophrenia: a developmental model of negative symptoms in drug-free patients. Am J Psychiatry 149:1543–1548PubMedGoogle Scholar
  62. Kemali D, Delvecchio M, Maj M (1982) Increased noradrenaline levels in CSF and plasma of schizophrenic patients. Biol Psychiatry 17:711–717PubMedGoogle Scholar
  63. Kirkpatrick B, Carpenter WT, Maeda K, Buchanan RW, Breier A, Tamminga CA (1992) Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients. Biol Psychiatry 32:1049–1054PubMedCrossRefGoogle Scholar
  64. Ko GN, Unnerstall JR, Kuhar MJ, Wyatt RJ, Kleinman JE (1986) Alpha-2 adrenergic agonist binding in schizophrenic brains. Psychopharmacology Bull 22:1011–1016Google Scholar
  65. Ko GN, Jimerson DC, Wyatt RJ, Bigelow LB (1988) Plasma 3-methoxy-4-hydroxyphenylglycol changes associated with clinical state and schizophrenic subtype. Arch Gen Psychiatry 45:842–846PubMedGoogle Scholar
  66. Kovelman JA, Scheibel AB (1984) A neurohistological correlate of schizophrenia. Biol Psychiatry 19:1601–1621PubMedGoogle Scholar
  67. Lake CR, Sternberg DE, van Kammen DP, Ballenger JC, Ziegler MG, Post RM, Kopin IJ, Bunney WE (1980) Schizophrenia: elevated cerebrospinal fluid norepinephrine. Science 207:331–333PubMedCrossRefGoogle Scholar
  68. Lai S, Nair NPV, Thavundayil JX, Monks RC, Gudya H (1983) Clonidine-induced growth hormone secretion in chronic schizophrenia. Acta Psychiatr Scand 68:82–88CrossRefGoogle Scholar
  69. Lambert GW, Eisenhofer G, Cox HS, Hörne M (1991) Direct determination of homovanillic acid release from the human brain, an indicator of central dopaminergic activity. Life Sci 49:1061–1072PubMedCrossRefGoogle Scholar
  70. Liddle PF, Barnes TRE (1990) Syndromes of chronic schizophrenia. Br J Psychiatry 157:558–561PubMedCrossRefGoogle Scholar
  71. Lieberman JA, Kane JM, Gadaleta D, Brenner R, Lesser MS, Kinon B (1984) Methylphenidate challenge as a predictor of relapse in schizophrenia. Am J Psychiatry 141:633–638PubMedGoogle Scholar
  72. Lieberman JA, Jody D, Geister S, Alvir J, Loebel A, Szymanski S, Woaner M, Barenstein M (1993) Time course and biological correlates of treatment response in first-episode schizophrema. Arch Gen Psychiatry 50:369–376PubMedGoogle Scholar
  73. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI (1992) Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 149:1183,1188Google Scholar
  74. Maas JW, Contreras SA, Miller AL, Berman N, Bowden CL, Javors MA, Seleshi E, Weintraub S (1993a) Studies of catecholamine metabolism in schizophrenia/ psychosis-I. Neuropsychopharmacology 8:97–109PubMedGoogle Scholar
  75. Maas JW, Contreras SA, Miller AL, Berman N, Bowden CL, Javors MA, Seleshi E, Weintraub S (1993b) Studies of catecholamine metabolism in schizophrenia/ psychosis-II. Neuropsychopharmacology 8:111–116PubMedGoogle Scholar
  76. MacKay AV (1980) Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 137:379–383PubMedCrossRefGoogle Scholar
  77. Marder SR, van Kammen DP, Bunney WE Jr (1979) Prediction of drug-free improvement in schizophrenic psychosis. Arch Gen Psychiatry 36:1080–1085PubMedGoogle Scholar
  78. Matussek N, Ackenheil M, Hippius H, Müller F, Schröder H-Th, Schultes H, Wasilewski B (1980) Effect of Clonidine on growth hormone release in psychiatric patients and controls. Psychiatr Res 2:25–36CrossRefGoogle Scholar
  79. Mazure CM, Nelson JC, Jatlow PI, Bowers MB (1991) Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis. Biol Psychiatry 30:475–482PubMedCrossRefGoogle Scholar
  80. McGuffin P, Farmer A, Gottesman II (1987) Is there really a split in schizophrenia? The genetic evidence. Br J Psychiatry 150:581–592PubMedCrossRefGoogle Scholar
  81. McKusick VA (1969) On lumpers and splitters, or the nosology of genetic disease. Perspect Biol Med 12:298–301PubMedGoogle Scholar
  82. Moises HW, Gelernter J, Giuffra LA, Zarcone VP (1991) No linkage between D2 dopamine receptor gene region and schizophrenia. Arch Gen Psychiatry 48:643–647PubMedGoogle Scholar
  83. Mortimer AM (1992) Phenomenology, its place in schizophrenia research. Br J Psychiatry 161:293–297PubMedCrossRefGoogle Scholar
  84. Müller-Spahn F, Ackenheil M, Bondy B, May G, Rüther E (1985) Growth hormone response to graded doses of apomorphine HCl in normals and schizophrenic patients: relation to psychotic decompensation? In: Shagass C, Josiassen RC, Bridger WH, Weiss KJ, Stoff D, Simpson GM (eds) Biological psychiatry 1985. Elsevier Science, New York, pp 1074–1076Google Scholar
  85. Murray RM, O’Callaghan E, Castle DJ, Lewis SW (1992) A neurodevelopmental approach to the classification of schizophrenia. Schizophr Bull 18:319–332PubMedGoogle Scholar
  86. Neuchterlein KH, Dawson ME (1984) A heuristic vulnerability/stress model of schizophrenic episodes. Schizophr Bull 10:300–312Google Scholar
  87. Neuchterlein KH, Dawson ME, Gitlin M, Ventura J, Goldstein MJ, Snyder KS, Yee CM, Mintz J (1992) Developmental processes in schizophrenic disorders: Longitudinal studies of vulnerability and stress. Schizophr Bull 18:387–425Google Scholar
  88. Öhlund LS, Lindström LH, Öhman A (1992) Electrodermal orienting response and central nervous system dopamine and serotonin activity in schizophrenia. J Nerv Ment Dis 180:304–313PubMedCrossRefGoogle Scholar
  89. Pandey GN, Janicak PG, Javaid JI, Davis JM (1989) Increased 3H-clonidine binding in the platelets of patients with depressive and schizophrenic disorders. Psychiatry Res 28:83–88CrossRefGoogle Scholar
  90. Parnas J, Cannon TD, Jacobsen B, Schulsinger H, Schulsinger F, Mednick SA (1993) Lifetime DSM-III-R diagnostic outcomes in the offspring of schizophrenic mothers. Results from the Copenhagen high-risk study. Arch Gen Psychiatry 50:707–714PubMedGoogle Scholar
  91. Penrose LS (1952) Measurement of pleiotropic effects in phenyl ketonuria. Ann Eugenics 18:120–124CrossRefGoogle Scholar
  92. Peters JL, van Kammen DP, Gelernter J, Yao JK, Shaw D (1990) Neuropeptide Y-like immunoreactivity in schizophrenia: relationships with clinical measures. Schizophr Res 3:287–294PubMedCrossRefGoogle Scholar
  93. Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki E, Potter WZ (1990) Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry 47:641–648PubMedGoogle Scholar
  94. Post RM, Fink E, Carpenter WT, Goodwin FK (1975) Cerebrospinal fluid amine metabolites in acute schizophrenia. Arch Gen Psychiatry 32:1063–1069PubMedGoogle Scholar
  95. Post RM, Gold PW, Rubinow DR, Bunney WE Jr, Ballenger JC, Goodwin FK (1983) Cerebrospinal fluid as neuroregulatory pathway. Peptides in neuropsychiatry illness. In: Wood JH (ed) Neurobiology of cerebrospinal fluid, 2. Plenum New York, pp 107–141Google Scholar
  96. Rapaport MH, McAllister CG, Pickar D, Nelson DL, Paul SM (1989) Elevated levels of soluble interleukin 2 receptors in schizophrenia (letter). Arch Gen Psychiatry 46: 291–292PubMedGoogle Scholar
  97. Reveley MA, Reveley AM, Clifford CA, Murray RM (1983) Genetics of platelet MAO activity in discordant schizophrenic and normal twins. Br J Psychiatry 142:560–565PubMedCrossRefGoogle Scholar
  98. Rice HE, Smith CB, Silk KR, Rosen J (1984) Platelet alpha2-adrenergic receptors in schizophrenic patients before and after phenothiozine treatment. Psychiatry Res 12:69–77PubMedCrossRefGoogle Scholar
  99. Roberts E (1973) An hypothesis suggesting that there is a defect in the GABA system in schizophrenia. An essay. Neurosci Res Prog Bull 10:468–482Google Scholar
  100. Rotrosen J, Miller AD, Mandio D, Traficante LJ, Gershon S (1978) Reduced PGE1 stimulated 3H-cAMP accumulation in platelets from schizophrenics. Life Sci 23: 1989–1996PubMedCrossRefGoogle Scholar
  101. Scheinin M, Karhuvaara S, Ojala-Karlsson P, Kallio A, Koulu M (1991) Plasma 3,4-dihydroxyphenylglycol (DHPG) and 3-methoxy-4-hydroxyphenylglycol (MHPG) are insensitive indicators of α2-adrenoceptor mediated regulation of norepinephrine release in healthy human volunteers. Life Sci 49:75–84PubMedCrossRefGoogle Scholar
  102. Seeman P, Ulpian C, Bergeron C, Riederer P, Jellinek K, Gabriel E, Reynolds GP, Tourtelotte WW (1984) Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science 225:728–731PubMedCrossRefGoogle Scholar
  103. Siever LJ, Silverman JM, Horvath TB, Klar H, Coccaro E, Keefe RSE, Pinkham L, Rinaldi P, Mohs RC, Davis KL (1990) Increased morbid risk for schizophreniarelated disorders in relatives of schizotypal personality disordered patients. Arch Gen Psychiatry 47:634–640PubMedGoogle Scholar
  104. Slater E (1947) Genetic causes of schizophrenic symptoms. Monatsschr Psychiatrie Neurol 113:50–58 (Reprinted in Man, mind and heredity, selected papers of Eliot Slater on psychiatry and genetics. Johns Hopkins Press, Baltimore, 1971)Google Scholar
  105. Stein L, Wise CD (1971) Possible etiology of schizophrenia: progressive damage to the noradrenergic reward system by 6-hydroxydopamine. Science 171:1032–1036PubMedCrossRefGoogle Scholar
  106. Steinhauer SR, van Kammen DP, Colbert K, Peters JL, Zubin J (1992) Pupillary constriction during haloperidol treatment as a predictor of relapse following drug withdrawal in schizophrenic patients. Psychiatry Res 43:287–298PubMedCrossRefGoogle Scholar
  107. Sternberg DE, van Kammen DP, Lake CR, Ballenger JC, Marder SR, Bunney WE Jr (1981) The effect of pimozide on CSF norepinephrine in schizophrenia. Am J Psychiatry 138:1045–1051PubMedGoogle Scholar
  108. Sternberg DE, Charney DS, Heninger GR, Leckman JF, Hafstad KM, Landis DH (1981) Impaired presynaptic regulation of norepinephrine in schizophrenia. Effects of Clonidine in schizophrenic patients and normal controls. Arch Gen Psychiatry 39: 285–289Google Scholar
  109. Sternberg DE, van Kammen DP, Lerner P, Ballenger JC, Marder SR, Post RM, Bunney WE (1983) CSF dopamine beta-hydroxylase in schizophrenia. Arch Gen Psychiatry 40:743–747PubMedGoogle Scholar
  110. Strauss JS, Hafez H, Lieberman P, Harding CM (1985) The course of psychiatric disorder. III. Longitudinal principles. Am J Psychiatry 142:289–296PubMedGoogle Scholar
  111. Subotnik KL, Nuechterlein KH (1988) Prodromal signs and symptoms of schizophrenic relapse. J Abnorm Psychol 97:405–412PubMedCrossRefGoogle Scholar
  112. Terenius L, Wahlstrom A, Lindstrom L, Widerlöv (1976) Increased CSF levels of endorphines in chronic psychosis. Neurosci Lett 3:157–162PubMedCrossRefGoogle Scholar
  113. Torrey EF, Peterson MR (1976) The viral hypothesis of schizophrenia. Schizophr Bull 2:136–146PubMedGoogle Scholar
  114. Tsuang MT, Lyons MJ, Faraone SV (1990) Heterogeneity in schizophrenia. Conceptual models and analytic stategies. Br J Psychiatry 156:17–26PubMedCrossRefGoogle Scholar
  115. van der Velde CD (1976) Variability in schizophrenia. Reflection of a regulatory disease. Arch Gen Psychiatry 33:489–496PubMedGoogle Scholar
  116. van Kammen DP (1977) Gamma-aminobutyric acid (GABA) and the dopamine hypothesis of schizophrenia. Am J Psychiatry 134:138–143PubMedGoogle Scholar
  117. van Kammen DP (1991) The biochemical basis of relapse and drug response in schizophrenia: review and hypothesis. Psychol Med 21:881–895PubMedCrossRefGoogle Scholar
  118. van Kammen DP, Kelley M (1991) Dopamine and norepinephrine activity in schizophrenia: an integrative perspective. Schizophr Res 4:173–191PubMedCrossRefGoogle Scholar
  119. van Kammen DP, Sternberg DE (1980) CSF studies in schizophrenia. In: Wood JH (ed) Neurobiology of cerebrospinal fluid, vol I. Plenum, New York, pp. 719–742Google Scholar
  120. van Kammen DP, van Kammen WB (1984) The amphetamine challenge test in schizophrenia: a stress response? In: Usdin E, Kvetnansky R, Axelrod J (eds) Stress: the role of catecholamines and other neurotransmitters, vol 2. Gordon & Breach Science Publishers, London, pp 957–966Google Scholar
  121. van Kammen DP, Docherty JP, Bunney WE Jr (1982a) Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment. Biol Psychiatry 17:233–242PubMedGoogle Scholar
  122. van Kammen DP, Docherty JP, Marder SR, Rayner JN, Bunney WE Jr (1982b) Longterm pimozide pretreatment differentially affects behavioral responses to dextroamphetamine in schizophrenia. Arch Gen Psychiatry 39:275–281PubMedGoogle Scholar
  123. van Kammen DP, Bunney WE Jr, Docherty JP, Marder SR, Ebert MH, Rosenblatt JE, Rayner JN (1982c) D-amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia. Am J Psychiatry 139:991–997PubMedGoogle Scholar
  124. van Kammen DP, Peters J, van Kammen WB (1986a) Cerebrospinal fluid studies of monoamine metabolism in schizophrenia. In: Roy A (ed) Schizophrenia: Psychiatric Clinics of North America. WB Saunders, Philadelphia, pp 81–97Google Scholar
  125. van Kammen DP, van Kammen WB, Mann LS, Seppala T, Linnoila M (1986b) Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy. Arch Gen Psychiatry 43:978–983PubMedGoogle Scholar
  126. van Kammen DP, van Kammen WB, Peters JL, Goetz K, Neylan T (1988) Decreased slow-wave sleep and enlarged lateral ventricles in schizophrenia. Neuropsychopharmacology 1:265–271PubMedGoogle Scholar
  127. van Kammen DP, Peters J, van Kammen WB, Nugent A, Goetz KL, Yao J, Linnoila M (1989) CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal. Biol Psychiatry 26:176–188PubMedCrossRefGoogle Scholar
  128. van Kammen DP, Peters J, Yao J, McAdam D, Mouton A, Breeding W (1990) Prediction of relapse following neuroleptic withdrawal: the role of noradrenaline. Clin Neuropharmacology 13:436–437CrossRefGoogle Scholar
  129. van Kammen DP, Peters J, Yao J, Neylan T, Beuger M, Pontius E, O’Connor DT (1992) CSF chromogranin A-like immunoreactivity in schizophrenia: assessment of clinical and biochemical relationships. Schizophr Res 6:31–39CrossRefGoogle Scholar
  130. van Kammen DP, Peters JL, Kelley ME, Gilbertson MW, Gurklis JA, O’Connor DT (1994) CSF dopamine β-hydroxylase in schizophrenia: associations with premorbid functioning and brain CT scan measures. Am J Psychiatry (in press)Google Scholar
  131. van Rossum JM (1966) The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn 160:492–494PubMedGoogle Scholar
  132. Ventura J, Nuechterlein KH, Hardesty JP, Gitlin M (1992) Life events and schizophrenic relapse after withdrawal of medication. Br J Psychiatry 161:615–620PubMedCrossRefGoogle Scholar
  133. Verhoeven WMA, van Praag HM, van Ree JM, De Wied D (1979) Improvement of schizophrenic patients treated with [des-tyr1]-γ-endorphin (DT γE). Arch Gen Psychiatry 36:294–298PubMedGoogle Scholar
  134. Weinberger DR (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660–669PubMedGoogle Scholar
  135. Widerlöv E (1988) A critical appraisal of CSF monoamine metabolite studies in schizophrenia. Ann NY Acad Sci 537:309–323PubMedCrossRefGoogle Scholar
  136. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue C-Y, Cooper TB, Brodie JD (1989) Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 146:905–908PubMedGoogle Scholar
  137. Wong DF, Wagner HN Jr, Tune LE, Dannais RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, Ravert HT, Wilson AA, Toung JKT, Malat J, Williams JA, O’Tuama LA, Snyder SH, Kuhar MJ, Gjedde A (1986) Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234: 1558–1563PubMedCrossRefGoogle Scholar
  138. Yao JK, van Kammen DP (1994) Red blood cell dynamics in schizophrenia. I. Membrane fluidity. Schizophr Res 11:209–216PubMedCrossRefGoogle Scholar
  139. Zubin J, Steinhauer S (1981) How to break the logjam in schizophrenia. J Nerv Ment Dis 169:477–492PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • D. P. Van Kammen
    • 1
  1. 1.Department of PsychiatryUniversity of Pittsburgh School of Medicine, Chief of Staff, Highland Drive VAMCPittsburghUSA

Personalised recommendations